

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 43/00, 49/00, 49/02, 9/133, 9/127	A1	(11) International Publication Number: WO 92/01068 (43) International Publication Date: 23 January 1992 (23.01.92)
---	----	--

(21) International Application Number: PCT/US91/03831
(22) International Filing Date: 30 May 1991 (30.05.91)

(30) Priority data:
530,847 30 May 1990 (30.05.90) US
610,204 5 November 1990 (05.11.90) US

(71) Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US). NAVAL RESEARCH LABORATORY [US/US]; Code 6090, 455 Overlook Avenue, S.W., Washington, DC 20375-5000 (US).

(72) Inventors: PHILLIPS, William, T. ; 314 Rosemary, San Antonio, 78209 (US). KLIPPER, Robert, W. ; 9519 Bowen, San Antonio, 78250 (US). TIMMONS, James, H. ; 10029 100th Avenue S.W., Tacoma, WA 98498 (US). RUDOLPH, Alan, S. ; 3447 Everette Drive, Bowie, MD 20716 (US).

(74) Agent: KITCHELL, Barbara, S.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).

(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published

*With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: ^{99m}Tc LABELED LIPOSOMES

(57) Abstract

The invention relates to the efficient preparation of radionuclide labeled liposomes and radionuclide-labeled liposome-encapsulated protein. In particular, a ^{99m}Tc carrier is used to label preformed liposomes or liposome-encapsulated hemoglobin. ^{99m}Tc-labeled liposomes and liposome-encapsulated ^{99m}Tc labeled hemoglobin are highly stable *in vitro* and *in vivo* and are suitable for a variety of clinical uses, including biodistribution imaging studies. The invention also relates to a method of labeling neutrophils using ^{99m}technetium-labeled liposomes or liposome-encapsulated hemoglobin. A kit method useful for the convenient preparation of ^{99m}Tc-labeled liposomes or liposome-encapsulated hemoglobin for clinical use is also disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

^{99m}Tc LABELED LIPOSOMES

This is a continuation-in-part of U.S. Patent Application Serial No. 07/530,847, filed May 30, 1990.

5

The United States Government may have certain rights in the present invention pursuant to the terms of Grant No. N 00014-89-K-0077 awarded by the Office of Naval Research.

10

The invention relates to a rapid and highly efficient method of labeling liposomes and liposome-encapsulated protein. In particular, the method relates to radionuclide labeling of preformed liposomes with or without encapsulated protein by means of a radionuclide carrier characterized as being membrane diffusible.

15

Table 1 is a list of abbreviations used.

20

Table 1

	cpm	counts per minute
	DTPA	diethylenetriaminepenta-acetic acid
	GBq	gigabequerels
25	HMPAO	hexamethylenepropylene amine oxime
	LEH	liposome-encapsulated hemoglobin
	PBS	phosphate buffered saline
	PYP	pyrophosphate
	Tc	Technetium
30	LUV	large unilamellar vesicles

Liposomes are of considerable interest because of their value as carriers for diagnostic agents, particularly radiopharmaceuticals for tracer and imaging studies. Successful biodistribution studies, for example, require attachment of a radiolabel to the liposome. Unfortunately, the entrapment of water soluble radionuclides within the liposome is relatively inefficient. Another major problem in using liposomes is

35

-2-

their leakiness, resulting in limited usefulness for many applications (Hwang, K.J., in Liposomes from Biophysics to Therapeutics, M.J. Ostru, Ed., Marcel Dekker, New York, 1987).

5

Radioactive markers have been widely used as a non-invasive method for studying the distribution of drugs *in vivo*. The use of gamma emitting radioisotopes is particularly advantageous because, unlike beta-emitters, they can easily be counted in a scintillation well counter and do not require tissue homogenization prior to counting. In addition, gamma-emitters can be imaged with nuclear gamma cameras. With this type of imaging, the dynamic biodistribution can be followed non-invasively using consecutive one minute computer acquired scintigraphic images which are analyzed to calculate organ biodistribution curves.

The most common radiolabel used in diagnostic radiopharmaceuticals today is ^{99m}Tc . This radionuclide is produced from the beta decay of $^{99}\text{molybdenum}$ and has a half-life of 6 hours. It is widely available from a generator system at low cost and its relatively short half-life provides for safer and more convenient handling than other available radionuclides. Its gamma emission is in the range of 140 Kev which is an ideal range for producing high resolution images (Caride, V.J. and Sostman, H.D. in Liposome Technology, Vol. II, G. Gregoriadis, Ed., CRC Press, Boca Raton, 1984).

Heptavalent $^{99m}\text{TcO}_4^-$ is produced from the generator and since it is relatively unreactive, must be reduced to a lower oxidation state before use as a radiopharmaceutical. Stannous chloride is the most commonly used reducing agent (Barratt, G.M., Tuzel, N.S. and Ryman, B.E. in Liposome Technology, Vol. II, G. Gregoriadis, Ed., CRC Press, Boca Raton, 1984).

-3-

Radiolabeled complexes have been employed as a means for labeling liposomes. Isonitrile radionuclide complexes of Tc and other gamma-emitters appear to have use for labeling vesicles with lipid membranes, including red blood cells (U.S. Patent No. 4,452,774, Jones et al., June 5, 1984). Propylene amine oxime complexes with ^{99m}Tc are stable neutral lipophilic complexes which have been approved for radioimaging *in vivo* as an adjunct in the detection of altered regional cerebral perfusion (CeretecTM). These complexes which diffuse across cellular walls have been shown to localize in red blood cells, although radioactivity is readily washed from the cells. (U.S. Patent 4,789,736, Canning et al., Dec. 6, 1988 and U.S. Patent 4,615,876, Troutner et al., Oct. 7, 1986). Furthermore, the usefulness of these complexes is limited because the complexes are not stable. CeretecTM, for example, has a useful life of approximately 30 minutes.

The radionuclide of $^{111}\text{indium}$ (^{111}In) has found some use as an imaging agent. Multilamellar lipid vesicles labeled with ^{111}In using 8-hydroxyquinoline showed a labeling efficiency of 30% (Caride, V.J. and Sostman, H.D. *in* Liposome Technology, Vol. II, G. Gregoriadis, Ed., CRC Press, Boca Raton, 1984). Higher labeling efficiencies have been shown for loading ^{111}In into the aqueous compartment of liposomes. Acetylacetone, a water soluble lipophilic chelator, can be complexed with ^{111}In . This is then mixed with liposome-encapsulated nitrilotriacetic acid with subsequent formation of labeled nitrilotriacetic acid. The resulting labeled liposomes are unstable unless excess acetylacetone is removed by an ion exchange process (Beaumier, P.L. and Hwang, K.J., J. Nucl. Med., 23, 810-815 (1982)).

-4-

In general, labeling efficiency of 50-70% for ^{99m}Tc has been reported for multilamellar vesicles and 4-20% for small unilamellar vesicles when using stannous chloride to reduce the pertechnetate. A persistent
5 problem in all these methods is the removal of excess reducing agent as well as elimination of free pertechnetate. Separation can be done by gel filtration or dialysis, but there is often formation of a ^{99m}Tc -tin chloride colloid which is not readily distinguishable or
10 separable from the liposomes (Barratt, G.M., Tuzel, N.S. and Ryman, B.E. in Liposome Technology, Vol. II, G. Gregoriadis, Ed., CRC Press, Boca Raton, 1984). This confounds the results of biodistribution studies since interpretation may be subject to altered uptake
15 influenced by the labeled colloidal tin.

Attempts at labeling liposomes with imaging radiotracers have produced variable results (Barratt, G.M., Tuzel, N.S. and Ruman, B.E. in Liposome Technology,
20 Vol. II, G. Gregoriadis, Ed., CRC Press, Boca Raton, 1984; Caride, V.J. and Sostman, H.D. in Lipid Technology, Vol. II, G. Gregoriadis, Ed., CRC Press, Boca Raton, 1984; Caride, V.J., Nucl. Med. Biol., 17, 35-39 (1990); Hwang, K.J. in Liposomes from Biophysics to Therapeutics,
25 M.J. Ostro, Ed., Marcel Dekker, Inc., New York, 1987). Many radioisotope labels weakly bind to liposomes resulting in inaccurate biodistribution data. A more efficient imaging label procedure uses ^{111}In indium chloride ($^{111}\text{InCl}$) and nitrilotriacetic acid, a metal chelator
30 (Beaumier, P.L. and Hwang, K.J., J. Nucl. Med., 23, 810-815 (1982); Turner, A.F., Presant, C.A., Proffitt, R.T., Williams, L.E., Winsor, D.W., Werner, J.L., Radiology, 166, 761-765 (1988); Proffitt, R.T., Williams, L.E., Presant, C.A., Tin, G.W., Uliana, J.A., Gamble, R.C. and
35 Baldeschwieler, J.D., J. Nucl. Med., 24, 45-51 (1983). The nitrilotriacetic acid is incorporated into the

-5-

liposome during the manufacturing process. The preformed liposomes are then incubated for 30 minutes with $^{111}\text{InCl}$. Although the $^{111}\text{InCl}$ nitrilotriacetic acid labeling method has proven to be effective and the label tightly attached to the liposome, a heating step (60°C) is required, which adds to the time and inconvenience involved in the preparation. In a clinical situation convenience and speed are important. A further consideration is the expense of the ^{111}In radionuclide. The present cost of ^{111}In is approximately \$135/mCi while cost of $^{99\text{m}}\text{Tc}$, a superior imaging agent, is \$0.35/mCi. This difference is highly significant in determining cost of imaging procedures to the patient and in a decision by the health provider to offer such services.

Other labeling carriers have been tried. Small amounts of octadecylamine-DTPA in liposomes have been shown to rapidly label the liposomes with ^{67}Ga or $^{99\text{m}}\text{Tc}$ by chelation with efficient labeling, but over 30% of the label is lost after a 2 hour incubation in plasma (Hnatowich, D.J., Friedman, B., Clancy, and Novak, M. J. Nucl. Med., 22, 810-814 (1981)).

The reasons for instability of $^{99\text{m}}\text{Tc}$ labeled liposomes are not well understood, although instability may be related to the liposome surface charge. Recent work has shown that the *in vitro* methods currently used to assess the stability of labeled liposomes do not predict isotope stability *in vivo*, and that the nature of the binding between the isotope and the liposome surface is important in regulating *in vivo* isotope stability (Love, W.G., Amos, N., Williams, B.D., and Kellaway, I.W., J. Microencapsulation, 6, 103-113 (1989)). The result is that even when labeling methods appeared to be highly efficient, and little instability was demonstrated in plasma or serum, significant loss of label could occur

-6-

when the labeled liposomes were introduced into an animal or human.

Despite attempts to develop stable ^{99m}Tc -labeled liposomes, there has been little success. In a thoroughly detailed review of liposomal labeling with radioactive technetium, Barratt et al. noted that technetium labeling techniques vary widely in efficiency. Moreover, stability is generally recognized to be poor, especially *in vivo*. Most methods of labeling liposomes with ^{99m}Tc encapsulate the ^{99m}Tc during liposome manufacture. However, these encapsulation methods do not solve the problem of *in vivo* dissociation of ^{99m}Tc from the liposome. The dissociated ^{99m}Tc is usually visualized in the kidneys and bladder. These problems clearly illustrate that development of a reliable method to load high levels of ^{99m}Tc into liposomes without *in vivo* dissociation would be beneficial in view of the many clinical uses for radiolabeled liposomes (Hwang, K.J. in Liposomes from Biophysics to Therapeutics, M.J. Ostro, Ed., Marcel Dekker, New York, 1987).

There are numerous clinical applications for ^{99m}Tc -liposomes. Comparison studies of liposome scanning, bone scanning and radiography have been performed in inflammatory joint disease. Liposome scans have been shown to be positive only in clinically active inflammatory disease. The method has also been able to discriminate between different grades of joint tenderness, in contrast to bone scans (O'Sullivan, M.M., Powell, N., French, A.P., Williams, K.E., Morgan, J.R., and Williams, B.D., Ann. Rheum. Dis., 47, 485-491, 1988; Williams, B.D., O'Sullivan, M.M., Saggiu, G.S., et al., Ann. Rheum. Dis. (UK), 46, 314-318 (1987)). Other studies include the localization of abscesses (Morgan, J.R., Williams, K.E., Davies, R.L., et al., J. Med.

-7-

Microbiol., 14, 213-217 (1981); tumor scanning (Eisenhut, M., Therapiewoche (West Germany) 30, 3319-3325 (1980); lymph node imaging (Osborne, M.P., Richardson, V.J., Jeyasingh, K., Ryman, B.E., Int. J. Nucl. Med. Biol. (England) 6, 75-83 (1979; Yu, B., Chin. J. Oncol. (China) 10, 270-273 (1988); clearance in the human lung (Farr, S.J., Kellaway, I.W., Parry-Jones, D.R., Woolfrey, S.G., Int. J. Pharm. (Netherlands) 26, 303-316 (1985)); and infarction (Palmer, T.N. Caride, V.J., Caldecourt, M.A., Twickler, J., and Abdullah, V., Biochim. Biophys. Acta 797, 363-368 (1984)).

Other potential uses of a liposome label include cardiac gated blood pool angiography and gastrointestinal bleeding detection. The most commonly used process known as the modified *in vivo* technique is fairly lengthy and requires 2-3 injections into the patient. For red blood cell labeling, the patient is injected with 1-2 mg of stannous PYP (Callahan, R.J., et al., J. Nuclear Medicine 23, 315-318 (1982)). Fifteen minutes later a blood sample is withdrawn and incubated with $^{99m}\text{TcO}_4^-$ (free pertechnetate). The patient is then reinjected with the radiolabeled blood, the whole procedure requiring up to 1 hour. The major disadvantage of this technique is that the label is often poor and free pertechnetate is taken up in the stomach, resulting in intestinal contamination and making the results difficult to interpret. A rapid labeling technique would very likely alleviate this major problem, allowing improved cardiac and gastrointestinal bleeding detection imaging.

There is a distinct need for radiopharmaceutical materials that can be broadly applied to clinical applications and to biodistribution and bioimaging studies. ^{99m}Tc labeled liposomes would appear to be an ideal reagent but present methods of labeling liposomes

-8-

with ^{99m}Tc are generally inefficient. A far greater problem is the lack of *in vivo* stability of ^{99m}Tc labeled liposomes, thereby limiting their use and creating uncertainty in interpretation of results.

5

The present invention is the surprising discovery that incubation of encapsulated reducing agent with liposomes, radionuclide labeled liposomes having high *in vivo* stability can be readily and efficiently prepared.

10 The liposomes, preferably labeled with ^{99m}Tc , are useful in a wide range of clinical applications related to biodistribution and imaging. Labeled liposome-encapsulated protein may also be prepared by this method and has also been shown to have high stability *in vivo*.

15

Stable ^{99m}Tc -labeled liposomes and ^{99m}Tc labeled liposome-encapsulated protein and their novel method of preparation are the subject of the present invention. The method of preparation results in over 95% labeling efficiency and produces labeled liposomes that are surprisingly stable *in vivo* for relatively long periods of time. The labeled liposomes are excellent imaging agents.

25

Labeled liposomes (LL) may be prepared by incubating liposomes with a label, generally a radionuclide, in the form of a complex which acts as a carrier for the label. It has been found that labeling is surprisingly efficient when the incubating is performed in the presence of an antioxidant compound. The antioxidant compound may be present in the incubation mixture of labeled carrier and liposomes, but is most preferably incorporated within the liposome prior to incubation with the label carrier.

35

Liposome-encapsulated labeled protein (LELP) may also be prepared by this method in a manner analogous to

-9-

that of labeled liposome preparation. Liposome-encapsulated protein having an antioxidant present within the liposome is incubated with a label carrier complex until liposome-encapsulated labeled protein is formed.

5 It is not known to what extent the label should be membrane diffusable, although it appears that some lipophilic character is desirable and that the carrier is significantly associated with the membrane.

10 After incubation, excess labeled carrier and antioxidant may be washed from the LL or LELP. Since the labeling is so efficient, only a few percent of the initial radioactivity is found in the wash. In cases where the carrier and antioxidant are relatively
15 innocuous, the washing is optional and the labeled liposomes may be used directly after incubation. This would be the case, for example, when the antioxidant is glutathione and the carrier is HMPAO. If separation is desired, centrifugation at 10-20,000 x g may be used or,
20 a rapid and convenient separation may be effected with a syringe pack column attached to the syringe containing the labeled liposomes. The liposomes will pass in the void volume while any free radionuclide, pertechnetate for example, would be retained on the column. In a most
25 preferred labeling procedure for clinical use, a freeze dried preparation of ^{99m}Tc -HMPAO is reconstituted with $^{99m}\text{TcO}_4^-$ and immediately incubated at room temperature with liposomes or liposome-encapsulated hemoglobin for a period as short as 5 minutes prior to use in a patient.
30 Washing is not necessary.

In a novel aspect of the invention, it has been discovered that labeling is highly efficient when an antioxidant is encapsulated within preformed liposomes or
35 liposome-encapsulated protein. Liposomes to be labeled may be first incubated with the antioxidant. This

-10-

antioxidant/liposome mixture may then be washed, removing excess antioxidant not attached to the liposome surface. These prepared liposomes may then be incubated with the labeled carrier. Although the antioxidant may be added to the incubation mixture with liposomes or liposome-encapsulated protein, washed and then added to the label carrier, this procedure provides liposomal preparations that are less stable *in vivo*. This is so even though the initial labeling efficiency is quite high. Most preferably the antioxidant compound is an inorganic or organic reducing agent, for example Sn^{+2} or glutathione. Compounds with free sulfhydryl appear to be suitable, for example, cysteine, although compounds of general structure RSH where R is an alkyl group or other organic moiety capable of interaction with a liposome would also be expected to work. Relatively large moieties such as proteins may also function well, particularly enzymes such as superoxide dismutase, catalase or met-hemoglobin reductase. Ascorbic acid also induced efficient binding of the label within the liposome. The mechanism of this action is not known, particularly whether or not the antioxidant agent is involved in the binding. It is possible, at least in the case of a $^{99\text{m}}\text{Tc}$ -HMPAO, that presence of a reducing agent converts lipophilic $^{99\text{m}}\text{Tc}$ -HMPAO to a hydrophilic form that becomes trapped inside the liposome. In any event, binding affinity of $^{99\text{m}}\text{Tc}$ to liposomes or to LEH is relatively inefficient without antioxidant present. In earlier experiments, it was found that binding of the label was very efficient when LEH preparations obtained from Naval Research Laboratories (Washington, DC) were used, but labeling was poor when LEH was prepared as described in Example 1 but without glutathione or ascorbic acid. It was later found that where efficient labeling was achieved, glutathione had been present in the preparations.

-11-

Both the liposomes and the protein encapsulated within the liposome have binding affinity for the label. The precise type of interaction is not known except to say that an antioxidant such as glutathione was found to be necessary to keep the label tightly bound with the liposome, regardless of the presence of a protein.

The protein encapsulated in the liposomes is preferably hemoglobin, although other proteins binding to selected labels could be chosen. Encapsulation of substances within liposomes is well-known and techniques for encapsulation have been described (Hwang, K.J. in Liposomes from Biophysics to Therapeutics, M.J. Ostro, Ed., Marcel Dekker, Inc., New York, 1987). In particular, a method for encapsulating hemoglobin in liposomes has been described (Farmer et al., U.S. Patent No. 4,911,929, March 27, 1990). Hemoglobin appears to be preferred as the encapsulated protein because in its presence ^{99m}Tc , presently the most widely used radionuclide in nuclear medicine, is tightly bound within the liposome (Barratt, G.M., Tuzel, N.S. and Ryman, B.E. in Liposome Technology, Vol. II, G. Gregoriadis, Ed., CRC Press, Boca Raton, 1984). Nevertheless, there may be instances in which other labels would be desired for specific studies or clinical purposes and thus a different protein might change the binding properties of the label. Certain beta-emitters, for example, might be desired and such radionuclides might bind more or less tightly in the presence of albumin or another protein. On the other hand, in certain applications, increased disassociation of the label may be desirable, as in instances where the liposome is intended to deposit the label at target organs or body areas. The label would then be dispensed at the target area. In any event, it is contemplated that the protein encapsulated may be chosen with consideration of the desired effect.

-12-

Suitable proteins might include transferrin, myoglobin, myosin, insulin, globulin, casein, keratin, lectin, ferritin and elastin. In addition, certain fragments or subunits of proteins might also be useful, including the
5 β -chain of hemoglobin.

Denaturated as well as native proteins could be encapsulated within liposomes and used to bind a label. Partially denatured proteins might be useful as well,
10 particularly if more binding sites are exposed.

Several types of labels could be used of which radionuclides would be the most useful for medical applications. Examples of beta-emitters include ^{32}P , ^{35}S ,
15 ^{36}Cl , ^{24}Na , ^{32}K and ^{45}Ca . Positron-emitters such as ^{68}Ga , ^{82}Rb , ^{22}Na , ^{75}Br , ^{122}I and ^{18}F would be useful in computerized tomographic studies. Of particular interest are the gamma-emitting radionuclides, for example, ^{24}Na , ^{51}Cr , ^{59}Fe , ^{67}Ga , ^{86}Rb , $^{99\text{m}}\text{Tc}$, ^{111}In , ^{125}I and ^{195}Pt . $^{99\text{m}}\text{Tc}$ and ^{111}In have
20 been found particularly useful for imaging studies in human subjects.

In the incubation of liposomes or liposome-encapsulated protein with a labeled carrier, the carrier
25 must be capable of complexing with the desired radionuclide and also diffusing through the liposomal membrane. Generally this will require a carrier that is lipophilic and also sufficiently water soluble to permit efficient transfer within the water compartment of the
30 lipid vesicle. For the radionuclide $^{99\text{m}}\text{Tc}$, the preferred carrier is hexamethylenepropylene amine oxime. This carrier transports the metal across the bilayer membrane of the liposome and, presumably, may subsequently transfer $^{99\text{m}}\text{Tc}$ to the liposome, to the encapsulated
35 protein or may become entrapped as the undissociated hydrophilic-converted carrier complex.

-13-

It will be recognized that a preferred carrier will depend to some extent on the lipid composition and surface charge of the liposome which can be positive,
5 negative or neutral. A preferred carrier is HMPAO. This carrier readily crosses the membrane of negatively charged liposomes. Other carriers could be chosen on their ability to complex with the selected radionuclide and the efficiency of transport across the liposomal
10 membrane to mediate exchange with the encapsulated capture material.

Furthermore, special ligands on the liposome surface, oligosaccharides or immunoglobulins for example,
15 could also affect uptake of the carrier as well as targeting of the liposomes within the body. The synthesis of liposomes with charged or neutral surfaces having a wide variety of compositions is well known in the art. The selection of the appropriate liposome would
20 require some experimentation and would depend on the carrier chosen and in turn on the radionuclide required.

The labeling efficiency of this method is greater than 90% and stability *in vivo* is quite high, as
25 indicated in the examples. After more than 18 hours, 70% of the injected liposome-encapsulated ^{99m}Tc labeled hemoglobin was recovered *in vivo* from rabbit blood (Figure 7). An *in vivo* experiment with ^{99m}Tc labeled liposomes indicated that up to 96% of the initial label
30 remained associated with the liposomes after 1.5 hr, (Figure 10). No other method has reported this high stability *in vivo*. In fact, the present invention has overcome one of the most significant disadvantages in the use of ^{99m}Tc as a radiolabeling agent, i.e., the apparent
35 release of free technetium *in vivo*, therefore casting doubt that the radioimages are representative of intact

-14-

liposomes (Barratt, G.M., Tuzel, N.S. and Ryman, B.E. in Liposome Technology, Vol. II, G. Gregoriadis, Ed., CRC Press, Boca Raton, 1984)).

5 The present invention also contemplates the use of
99mTc labeled liposomes or liposome-encapsulated labeled
hemoglobin in kit form. Thus, in a preferred mode of
use, freeze dried liposomes or liposome-encapsulated
hemoglobin would be incubated with a radionuclide
10 carrier, such as 99mTc hexamethylenepropylene amine oxime,
before administration to patients or experimental
animals. Other radionuclides could be used as could
other encapsulated proteins besides hemoglobin, for
example albumin, as described in Example 2.

15 Example 4 illustrates the use of 99mTc labeled
liposome-encapsulated hemoglobin in biodistribution
studies, but it will be appreciated that appropriate
carriers could be used to transfer other gamma emitters
20 to capture agents within a liposome. For example, 111In,
125I and 67Ga. The method could also be applied to beta-
or positron emitters; for example, 32P, 35S or, in the
latter category, 68Ga and 18F. The distribution of the
label can be detected by means appropriate to the
25 emitter. Gamma emitters are commonly detected using well
established scintillation counting methods or nuclear
gamma cameras. Beta emitters can be detected by
radiation detection devices specific for beta particles
while positron emitters are determined using various
30 designs of a positron emission tomography apparatus.

 Likewise, the general method described in the
present invention would be particularly applicable to
magnetic resonance imaging, simply by preparing a
35 paramagnetically labeled liposome or liposome-
encapsulated carrier molecule, administering the labeled

-15-

liposome *in vivo* and determining the distribution of the paramagnetic label. The usual means for determining paramagnetic species is nuclear magnetic resonance detection. Bone marrow imaging has been shown particularly useful with ^{99m}Tc labeled liposomes which demonstrate a large amount of bone marrow uptake from the circulation several hours after administration (Figure 12). ^{99m}Tc labeled liposomes having an average size of about 0.05-0.1 μ appear to be most useful for this purpose. Larger liposomes would be expected to image in different areas, for example, the lungs or other organs. Clearly, one could expect to image different regions of the body by using different size ranges of labeled liposome preparations.

In another aspect of the invention, ^{99m}Tc labeled LEH is used to label neutrophils. Neutrophils incubated with labeled liposomes apparently phagocytized the labeled liposomes and became labeled with ^{99m}Tc . The 20% labeling achieved shows promise for developing a highly stable neutrophil label. This method could be used to achieve similar labeling with any phagocytized cell, for example monocytes or other cells that are capable of engulfing a labeled liposome. This could be controlled to some extent by the size and composition of the liposome employed.

Figure 1 is a graph showing the fractionation of liposome-encapsulated ^{99m}Tc labeled liposomes on a Sephadex G-200 column 70 hours after binding of the label to the encapsulated hemoglobin. All the ^{99m}Tc is associated with the liposomal fraction.

Figure 2 shows the percent ^{99m}Tc binding initially to liposomes using HMPAO where LEH is liposome-encapsulated hemoglobin and blanks are liposomes without encapsulated

-16-

material. There is no loss of the ^{99m}Tc label during the first wash.

Figure 3 shows the *in vitro* stability of ^{99m}Tc labeled liposomes in lactated Ringers solution at 2°C.

Figure 4 shows 11.8% initial binding of ^{99m}Tc to liposome-encapsulated albumin.

Figure 5 shows time activity curves acquired from imaging data of the heart, liver, spleen, bladder and lung of a rabbit injected with ^{99m}Tc labeled LEH.

Figure 6 shows various anatomical features seen on the image of a New Zealand rabbit infused with ^{99m}Tc -labeled LEH acquired at 2 hours labeling.

Figure 7 is a graph of ^{99m}Tc radioactive counts of capillaries drawn serially after infusion of 25 milliliters of ^{99m}Tc -labeled LEH at a concentration of 50 mg total lipid per milliliter into a 2 kilogram New Zealand rabbit.

Figure 8 shows the labeling of neutrophils incubated with ^{99m}Tc labeled liposome-encapsulated hemoglobin. The radioactivity labeling efficiency of the neutrophils is 10.7% after 1 hour of incubation and 21.2% after 20 hours of incubation.

Figure 9 shows the *in vitro* stability of ^{99m}Tc -labeled liposomes prepared using liposomes encapsulating 30 mM or 100 mM glutathione.

Figure 10 shows the *in vivo* stability of ^{99m}Tc -labeled liposomes prepared from liposomes containing 30 mM or 100 mM glutathione. Labeled liposome preparations

-17-

were injected into rabbits and blood samples taken at the times indicated.

Figure 11 is a chart comparing ^{99m}Tc -labeling efficiency and effect of washing on blank liposomes, liposomes encapsulating 20 mM glutathione, and liposome-encapsulated hemoglobin also entrapping either 20 mM glutathione or 100 mM glutathione.

Figure 12 is a gamma scintillation image of a rabbit after administration of ^{99m}Tc -labeled liposomes containing glutathione. The four frames are different images of the same rabbit. The top frames show the middle body taken at 30 minutes and 90 minutes. The lower frames show the top of the body, frame C, and the lower body, frame D, images taken after 20 hours.

Liposome-Encapsulated Protein

As discussed above, several different proteins as well as different liposomal compositions may be used to prepare liposomes and encapsulated labeled protein. Albumin is an example of a protein that can be encapsulated by the method described in Example 1 used to encapsulate hemoglobin. In a most preferred embodiment, hemoglobin is encapsulated in monolamellar negatively charged liposomes. Methods of producing liposome-encapsulated protein include a variety of methods, for example, reverse phase evaporation, homogenization and pressure extrusion. A method of producing liposome-encapsulated hemoglobin is described in Example 1. Other forms of hemoglobin can be substituted for bovine hemoglobin, including recombinant human hemoglobin. Well-known methods of encapsulation with liposomes could be employed to encapsulate proteins with special affinity for a desired label. The encapsulated protein need not

-18-

be a native molecule or even the entire molecule. For example, only the β -chain of hemoglobin might be encapsulated. Examples of other proteins that could be encapsulated include transferrin, myoglobin, myosin, ferritin, globulin, insulin, elastin, keratin, casein, hemoglobin fragments and other polypeptides.

Efficient binding of the label within the liposome requires the presence of a reductant, thought to act as an antioxidant, preferably glutathione which is most preferably encapsulated with the liposome-encapsulated protein before incubation with a label carrier. If glutathione is added to the liposome after the protein is encapsulated, the final labeled product is efficiently labeled but appears not to have high *in vivo* stability.

^{99m}Tc-labeled Liposomes

The discovery of an efficient labeling method for liposomes resulting in labeled liposomes that are stable *in vitro* and *in vivo* solves one of the more important problems in liposome labeling. The method is illustrated with the use of ^{99m}Tc-labeled HMPAO as a carrier to introduce the label into a preformed liposome. Glutathione, ascorbic acid or other suitable antioxidant is most preferably encapsulated within the liposome prior to incubation with a labeled carrier to achieve efficient labeling. Possibly glutathione or other reducing agents convert the ^{99m}Tc HMPAO complex into a more hydrophilic form that is retained inside the liposome (Ballinger, J.R., Reid, R.H. and Gulenchyn, K.Y., J. Nucl. Med., 29, 1998-2000(1988); Lang, J.J., J. Nucl. Med., 31, 1115 (1990); Ballinger, J., J. Nucl. Med., 31, 1115-1116 (1990)).

35

-19-

^{99m}Tc Carriers

The ^{99m}Tc carrier found most preferable is an alkylenepropyleneamine oxime that complexes with ^{99m}Tc and can be purchased as a lyophilized preparation (Ceretec™, Amersham, IL). In this form, HMPAO is mixed with sterile eluate from a technetium ^{99m}-Tc generator. The generator eluate may be adjusted to a radioactive concentration of between 0.37-1.11 GBq (10-30 mCi) in 5 ml by dilution with preservative-free, non-bacteriostatic saline prior to mixing with 0.5 mg of HMPAO. The ^{99m}Tc complex forms almost immediately and is then incubated with liposomes containing encapsulated reductant or liposome-encapsulated hemoglobin at room temperature for 5-15 minutes. Room temperature incubation is a significant advantage over other methods of liposome labeling presently used. ¹¹¹In, for example, can be retained within liposome-encapsulated nitrilotriacetic acid but the encapsulated nitrilotriacetic acid must be incubated with ¹¹¹indium chloride at 60°C for 30 minutes. Thus ^{99m}Tc labeled liposomes prepared by the method of the present invention could be used in the assessment of *in vivo* distribution of new liposome drug agents that contain proteins or other heat labile drugs, whereas the heat required for the preparation of the ¹¹¹In labeled liposome would denature or destroy any encapsulated heat sensitive material.

^{99m}Tc liposomes also have potential in assessing the effectiveness of targeting with liposomes having antibodies attached to the surface. Antibodies to infectious agents or to tumor cells would bind to the targeted areas allowing radioimaging and possible delivery of drugs to the site.

35

-20-

EXAMPLE 1Preparation of Liposome-Encapsulated Hemoglobin

5 Liposome components are: distearoyl
phosphatidylcholine (DSPC) (American Lecithin Company,
Atlanta, GA), supplied as Phospholipid 100-H composed of
95% hydrogenated distearoyl phosphatidylcholine and up to
5% lysophosphatidylcholine; cholesterol (Calbiochem, San
10 Diego, CA) at a purity of greater than 99% by TLC; and
Dimyristoyl phosphatidyl DL-glycerol (DMPG) (Avanti Polar
Lipids, Birmingham, AL) which was used without further
purification. d-Alpha-tocopherol (Sigma, St. Louis, MO)
was mixed in a 200 mg/ml solution in chloroform. All
15 lipids were dried down from chloroform stock solutions in
a mole ratio of 10:9:1 (DSPC:cholesterol:DMPG:alpha-
tocopherol) and stored overnight in a vacuum desiccator
to remove organic solvent. Samples were then rehydrated
with solutions of trehalose (Pfanstiehl Laboratories,
20 Waukegan, IL) in 30 mM phosphate buffered saline pH 7.4
and warmed in a water bath at 60°C for one hour.

The resultant multilamellar vesicles formed from
rehydration were reduced to large unilamellar vesicles
25 (LUVs) using a high shear, high pressure apparatus
(Microfluidics Corp., Boston, MA). The LUV's were then
frozen in liquid nitrogen and lyophilized. The resultant
dry sugar-lipid preparations were then hydrated with a
solution of concentrated (25g/ml) bovine hemoglobin (Hb)
30 (Biopure Corp., Boston, MA) containing 30 mM or 100 mM
glutathione or ascorbic acid and placed on an orbital
shaker at 4°C for 2 hours. These solutions were then run
through a microfluidizer to form LEH and centrifuged to
remove extravesicular hemoglobin and reducing agent
35 (14,000 x g for 1 hour). The resulting LEH was
concentrated by centrifugation and stored in the

-21-

refrigerator at 4°C or shell frozen using a bench top lyophilizer.

EXAMPLE 2

5

^{99m}Tc Labeling of Liposome-Encapsulated Hemoglobin

10 Liposome-encapsulated hemoglobin (prepared as described in Example 1 or purchased from Vestar, Inc., San Dimas, CA or Naval Research Laboratories, Washington, D.C.) was washed 3 times with phosphate buffered saline by centrifugation and resuspended with phosphate buffered saline to remove subcellular-sized debris and free hemoglobin. LEH containing glutathione or ascorbic acid
15 was resuspended in PBS to yield a hematocrit value of approximately 50. ^{99m}Tc (10 mCi) in 5 ml sterile water for injection was used to reconstitute hexamethylenepropylene amine oxime (HMPAO) supplied as a freeze dried preparation (Ceretec™, Amersham, Arlington
20 Heights, IL) for 5 min at room temperature. This mixture of ^{99m}Tc-HMPAO complex and glutathione was then incubated with LEH (10 mg - 1000 mg total lipid dose of LEH containing 2.5-300 mg intravesicular hemoglobin) for 5 minutes with intermittent swirling after which the radio-
25 labeled LEH was washed (centrifugation at 20,000 x g for 30 minutes) with PBS and the labeling efficiency determined (bound to pellet/total). LEH was then resuspended to a constant lipid dose for injection.

30 Fractionation of ^{99m}Tc-labeled LEH on Sephadex G-200 70 hours after binding is shown in Figure 1. The labeled LEH eluted with the void volume. There was insignificant detection of free ^{99m}Tc. Figure 2 indicates that liposomes without hemoglobin (blanks) bound less than 10%
35 of the ^{99m}Tc added to LEH preparations. The blanks were prepared as described in Example 1 for the preparation of

-22-

LEH except that during hydration no hemoglobin or glutathione were added.

The ^{99m}Tc -labeled LEH exhibited excellent *in vitro* stability over a period of at least 90 hours storage in lactated Ringer's solution, as shown in Figure 3 and in Figure 9. Figure 3 shows the stability of liposome-encapsulated labeled hemoglobin prepared from LEH purchased from Naval Research Laboratories and incubated with ^{99m}Tc -HMPAO without the addition of glutathione (glutathione is present as a result of the particular method of preparation of LEH). Figure 9 shows the stability of liposome-encapsulated labeled hemoglobin prepared as described above with glutathione present at a concentration of 20 mM or 100 mM.

Liposome-encapsulated albumin was prepared as described for hemoglobin except that glutathione was omitted from the incubation mixture. Approximately 12% of the label carried by the ^{99m}Tc -HMPAO became bound to the encapsulated albumin. One-third of the label was removed after two washings with PBS (see Figure 4).

EXAMPLE 3

25

^{99m}Tc -labeled Liposomes

Liposomes prepared as described in Example 1 above or purchased from a commercial source (Vestar, San Dimas, CA) and containing 30 mM or 100 mM glutathione were incubated with ^{99m}Tc -HMPAO. The percent of initial ^{99m}Tc associated with the liposomes was measured before and after washing and compared with the amount of label retained in liposome-encapsulated labeled hemoglobin. The results are shown in Figure 9 and Figure 11. There was virtually no loss of ^{99m}Tc label from liposomes or

-23-

liposome-encapsulated hemoglobin prepared by incubating with ^{99m}Tc -HMPAO in the presence of glutathione. Labeling efficiency was less than 20% when glutathione was absent and there was a loss of almost 50% of the label after a single wash.

In vivo stability of ^{99m}Tc labeled liposomes was 85% and 90% respectively for liposomes incubated in the presence of 30 mM and 100 mM glutathione when tested over a period of 1.5 hr. (Figure 10).

EXAMPLE 4

Animal Biodistribution Studies with ^{99m}Tc -labeled LEH

Young adult male New Zealand white rabbits (2.5-3.0 kg) were anesthetized intramuscularly with ketamine:xylazine at 50 mg/kg:10mg/kg respectively. While anesthetized, venous and arterial access lines were secured. The rabbit was then restrained in the supine position under a low energy, parallel hole collimator of a gamma camera and imaged for ^{99m}Tc activity at 140 Kev with a 20% window. Baseline blood samples were drawn and the metered (40 ml/kg/hr) injection of the LEH was begun. An aliquot of the injection material was reserved for lipid analysis and radioactive quantitation. Blood was then drawn at intervals to assess changes in blood chemistry, complete blood counts, the duration of LEH in the circulation and subsequent deposition and processing of the LEH by the organ systems. At 20 hours post-injection, the rabbit was sacrificed by anesthesia overdose and tissues recovered for quantitation and pathology study. Images acquired for the first two hours and at 20 hours were analyzed by drawing regions of interest around all organ systems (heart, lungs, anterior and posterior liver, spleen, kidneys, bladder and aorta)

-24-

within the camera field of view. Counts in these regions of interest were calculated at 1 min intervals for 2 hours and then at 20 hours. Counts were decay corrected to correct for radioactive decay. These data were
5 entered into a MacIntosh computer for graphic demonstration of changes in biodistribution occurring with time as shown in Figure 5. The levels of ^{99m}Tc distribution in the rabbit heart, liver, spleen and lungs are shown in Figure 6. Figure 12 shows the distribution
10 of the label concentrated in the bone marrow 20 hours after administration.

The in vivo recovery of ^{99m}Tc -labeled LEH from rabbit blood over a period of 18 hours is shown in Figure 7.
15

EXAMPLE 5

^{99m}Tc -Labeling of Neutrophils

20 Sixty ml of whole blood was drawn and diluted with 3 volumes of Hanks Buffered Salt Solution. Neutrophils were isolated with Ficol Hypaque centrifugation at 600 x g for 20 minutes. Recovered neutrophils were washed x 2 with a lymphocyte maintenance medium. The neutrophils
25 were counted and 2 separate aliquots of 10^7 neutrophils were incubated with radiolabeled LEH for 1-20 hours at 37°C. The suspensions were counted and then centrifuged to yield a neutrophil pellet. The pellet was resuspended and washed x 2. The labeling efficiency was then
30 determined (bound to white cell pellet/total). As shown in Figure 8, over 20% of the initial activity was incorporated by the neutrophils after 20 hours of incubation.

-25-

EXAMPLE 6Bone Marrow Imaging

5 Two rabbits were injected with ^{99m}Tc labeled
liposomes prepared as described in Example 3. Twenty hr
after administration, images were taken on the whole
animal using a gamma scintillation camera set at 140 KeV
with a 20% window. As shown in Figure 12, the majority
10 of the radionuclide had left the circulation and was
concentrated in the bone marrow.

The present invention has been described in terms of
particular embodiments found by the inventors to comprise
15 preferred modes of practice of the invention. It will be
appreciated by those of skill in the art that in light of
the present disclosure numerous modifications and changes
can be made in the particular embodiments exemplified
without departing from the intended scope of the
20 invention. For example, various modifications of the
liposomal surfaces could be used to better target certain
organs, or glutathione analogs or derivatives could be
used to modify properties of the carrier without
affecting the intended nature or practice of the
25 invention. All such modifications are intended to be
included within the scope of the claims.

The references cited within the text are
incorporated herein by reference to the extent that they
30 supplement, explain, provide a background for or teach
methodology, techniques and/or compositions employed
herein.

-26-

CLAIMS:

1. A method of preparing radionuclide labeled liposomes, comprising incubating liposomes with a label-carrier complex and an antioxidant, said carrier being characterized as membrane diffusible and said incubating being for a period of time sufficient to form labeled liposomes.
2. A method of preparing liposome-encapsulated labeled protein, comprising incubating liposome-encapsulated protein with a label-carrier complex and an antioxidant, said carrier being characterized as membrane diffusible and said incubating being for a period of time sufficient to form liposome-encapsulated labeled protein.
3. The method of claim 1 or claim 2 wherein excess label-carrier complex is washed from the labeled liposomes or the liposome-encapsulated labeled protein.
4. The method of claim 1 or claim 2 wherein the antioxidant is a reductant.
5. The method of claim 1 or claim 2 wherein the antioxidant is glutathione or cysteine.
6. The method of claim 1 or claim 2 wherein the antioxidant is ascorbic acid.

-27-

7. The method of claim 1 or 2 wherein the antioxidant is a reducing metal cation.
- 5 8. The method of claim 2 wherein the liposome-encapsulated protein is hemoglobin.
- 10 9. The method of claim 2 wherein the liposome-encapsulated protein is a ^{99m}Tc-binding protein selected from the group consisting of albumin, transferrin, myoglobin, myosin, insulin, globulin, casein, keratin, lectin, ferritin and elastin.
- 15 10. The method of claim 2 wherein the protein is at least partially denatured, said at least partially denatured protein binding a radionuclide label with greater affinity than the carrier.
- 20 11. The method of claim 2 wherein the protein is the β -chain of hemoglobin.
- 25 12. The method of claim 1 or claim 2 wherein the label is a radionuclide.
- 30 13. The method of claim 1 or claim 2 wherein the label is a gamma-emitting radionuclide selected from a group consisting of ²⁴Na, ⁵¹Cr, ⁵⁹Fe, ⁶⁷Ga, ⁸⁶Rb, ^{99m}Tc, ¹¹¹In, ¹²⁵I and ¹⁹⁵Pt.

35

-28-

14. The method of claim 1 or claim 2 wherein the label is a beta-emitting radionuclide selected from a group consisting of ^{32}P , ^{35}S , ^{36}Cl , ^{24}Na , ^{32}K and ^{45}Ca .

5

15. The method of claim 1 or claim 2 wherein the label is a positron-emitting radionuclide selected from a group consisting of ^{68}Ga , ^{82}Rb , ^{22}Na , ^{75}Br , ^{124}I and ^{18}F .

10

16. The method of claim 1 or claim 2 wherein the carrier is an alkyleneamine oxime.

15

17. The method of claim 1 or claim 2 wherein the label-carrier complex is $^{99\text{m}}\text{Tc}$ -hexamethylenepropylene amine oxime.

20

18. The method of claim 2 wherein the liposome-encapsulated labeled protein is liposome-encapsulated $^{99\text{m}}\text{Tc}$ -hemoglobin.

25

19. The method of claim 1 or claim 2 wherein the charge on the liposome is negative.

30

20. A method of determining *in vivo* biodistribution, comprising the steps:

35

administering to an animal an amount of labeled liposome having encapsulated reducing agent or liposome-encapsulated radionuclide-labeled hemoglobin sufficient for detection by radiation detection means; and

-29-

determining *in vivo* biodistribution.

21. The method of claim 20 wherein the radionuclide
5 labeled hemoglobin is ^{99m}Tc-hemoglobin.

22. The method of claim 20 wherein the labeled liposome
is ^{99m}Tc-labeled liposome.
10

23. A method for labeling neutrophils, comprising the
steps:

15 incubating neutrophils with liposome-encapsulated
^{99m}Tc-hemoglobin or ^{99m}Tc-labeled liposomes for a
time sufficient to form ^{99m}Tc-labeled
neutrophils; and

20 separating the ^{99m}Tc-labeled neutrophils.

24. A method of magnetic resonance imaging, comprising
the following steps:

25 incubating a paramagnetic label with a carrier
molecule for a time sufficient to form a
paramagnetic-carrier molecule complex;

30 adding the paramagnetic-carrier molecule complex to
liposomes or liposome-encapsulated hemoglobin
wherein a reducing agent is encapsulated within
the liposome;

35 separating the paramagnetic liposomes or liposome-
encapsulated paramagnetic hemoglobin;

-30-

administering *in vivo* an amount of the paramagnetic liposomes or liposome-encapsulated paramagnetic hemoglobin sufficient for detection by magnetic resonance means; and

determining distribution of the paramagnetic liposomes or liposome-encapsulated hemoglobin.

25. A kit useful for preparing radiolabeled liposomes or liposome-encapsulated radiolabeled protein comprising:

a transporter being compartmentalized to receive one or more container means in close confinement therein;

a first container means comprising a carrier, said carrier being capable of binding to a radionuclide; and

a second container means comprising liposomes encapsulating a reducing agent or liposome-encapsulated protein and reducing agent.

26. The kit of claim 25 wherein the carrier, the liposomes and the liposome-encapsulated protein are lyophilized.

27. The kit of claim 25 wherein the carrier is hexamethylenepropylene amine oxime, propylene amine oxime or an alkylpropyleneamine derivative.

-31-

28. The kit of claim 25 wherein the radionuclide is ^{99m}Tc , ^{67}Ga or ^{111}In .
- 5 29. The kit of claim 25 wherein the protein is hemoglobin, albumin, myoglobin, transferrin or ferritin.
- 10 30. The kit of claim 25 wherein the reducing agent is glutathione or ascorbic acid.
- 15 31. A radionuclide-containing vesicle comprising ^{99m}Tc bound to liposomes or liposome-encapsulated protein wherein a reducing agent is encapsulated with the liposomes or liposome-encapsulated protein.
- 20 32. The vesicle of claim 31 wherein the liposome-encapsulated protein is hemoglobin.
- 25 33. The vesicle of claim 31 wherein the reducing agent is glutathione or ascorbic acid.
- 30 34. A method of imaging bone marrow comprising the steps:
- administering to an animal or human the radionuclide vesicle of claim 31 in an amount sufficient for detection by radiation detection means; and
- 35 determining distribution of the labeled vesicle after the vesicle has concentrated in the bone marrow.

-32-

35. The method of claim 34 wherein the imaging is determined about 20 hours after administration.

5

36. The method of claim 34 wherein the vesicles are liposomes about 0.1-0.2 μ in size.

1/2




FIGURE 1

2/2




FIGURE 2

3/22




FIGURE 3

4/12




FIGURE 4




FIGURE 5

4/12




FIGURE 6

7/12




FIGURE 7

8/12




FIGURE 8

9/12




FIGURE 9

10/12




FIGURE 10

11/12





FIGURE 11

12/12



GEN ANALYSIS

FIGURE 12

Printed on Monday 10/01/90 at 11:50

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/03831

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC (5): A61K 43/00 49/00, 49/02 9/133, 9/127		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	424/1.1, 450, 9; 534/14; 536/829	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
APS MESSENGER TEXT SEARCH, FILE USPAT		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	US, A, 4,707,544 (JONES ET AL.) 17 November 1987 See column 6, line 48 - col. 7, line 18.	1-3,12-17, 25-30
A	US, A, 4,911,929 (FARMER ET AL.) 27 March 1990 See the entire document.	8,11,18,19
T	US, A, 4,935,223 (PHILLIPS) 19 June 1990	
A	Eur. J. Nucl. Med., volume 15, issued 1989 K. Nakamura et al., "The behavior of ^{99m} Tc- hexamethy/propyleneamineoxime (^{99m} Tc-HMPAO) in blood and brain," See pages 100-103.	20-22
A	J. Nucl. Med., volume 15, number 8, issued 1974 M. K. Dewanjee, "Binding of ^{99m} Tc ion to Hemoglobin," see pages 703-706.	8,11,20-22
A	Nucl. Med Biol, volume 16, number 6, issued 1989 A. Takeeda et al., "Intensificatio of Tumor Affinity of ^{99m} Tc - DL-Homocysteine by Cooperative Use of SH-containing Compounds," see pages 581-585.	4-7
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 16 December 1991		Date of Mailing of this International Search Report 20 DEC 1991
International Searching Authority ISA/US		Signature of Authorized Officer <i>John M. Covert</i> John M. Covert

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A	J. Nucl. Med., volume 29, number 12, issued 1988, J. R. Ballinger et al., "Technetium - 99m HM-PAO Stereoisomers: Differences in Interaction with Glutathione," see pages 1998-2000.	4-7
A	C. De Labriolle-Vaylet et al., "Morphological and Functional Status of Leukocytes Labelled with ^{99m} Technefium HMPAO," <u>Radiolabelled Cellular Blood Elements</u> , published 1990 by Wiley-Liss Inc., see pages 119-123.	23

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	J. Nucl. med., volume 23, number 9, issued 1982, "An efficient method for Leading Indium - 111 into Liposomer Using Acetylacetone," P. L. Beaumier et al., see pages 810-811.	
A	US, A, 4,335,095 (KELLY) 15 JUNE 1982	
A	Investigative Radiology, volume 23, number 12, issued 1988, "Gadolinium - DTPA Liposomes as a Potential MRI Contrast Agent Work in Progress," Unger et al., see pages 928-232.	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.